Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition

Lorenza Rimassa, Silvia Bozzarelli, Filippo Pietrantonio, Stefano Cordio, Sara Lonardi, Laura Toppo, Alberto Zaniboni, Roberto Bordonaro, Maria Di Bartolomeo, Gianluca Tomasello, Vincenzo Dadduzio, Maria Chiara Tronconi, Chiara Piombo, Laura Giordano, Annunziata Gloghini, Luca Di Tommaso, Armando Santoro

Research output: Contribution to journalArticlepeer-review

Fingerprint

Dive into the research topics of 'Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition'. Together they form a unique fingerprint.

Medicine & Life Sciences